Page last updated: 2024-09-03

clofarabine and Leukemia, Myeloid, Acute

clofarabine has been researched along with Leukemia, Myeloid, Acute in 145 studies

Research

Studies (145)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (0.69)	18.2507
2000's	26 (17.93)	29.6817
2010's	104 (71.72)	24.3611
2020's	14 (9.66)	2.80

Authors

Authors	Studies
Bierings, M; Boelens, JJ; Bresters, D; de Koning, CCH; Kollen, WJ; Lankester, AC; Lindemans, CA; Nierkens, S; Versluijs, AB	1
Arman Bilir, O; Ozbek, NY; Sengul Emeksiz, Z; Toyran, M; Yilmaz Topal, O	1
Bakunina, K; Breems, DA; Cloos, J; Cornelissen, JJ; de Wreede, LC; Gjertsen, BT; Koster, EAS; Löwenberg, B; Manz, MG; Ossenkoppele, GJ; Pabst, T; Passweg, J; Putter, H; Valk, PJM; van der Holt, B; Versluis, J	1
Agrawal, AK; Forlenza, CJ; Kernan, NA; Mauguen, A; Ramaswamy, K; Roshal, M; Shukla, N; Steinherz, PG; Sulis, ML; Trippett, T	1
Ali, S; Burnett, AK; Cahalin, P; Clark, RE; Hills, RK; Kjeldsen, L; Russell, NH; Thomas, IF	1
Ahmed, S; Alousi, A; Andersson, BS; Bashir, Q; Bassett, R; Champlin, RE; Chen, J; Ciurea, S; Cool, R; Gulbis, A; Hosing, C; Kawedia, J; Kebriaei, P; Kornblau, S; Ma, J; Myers, A; Nieto, Y; Oran, B; Parmar, S; Popat, UR; Rezvani, K; Shah, N; Shpall, E; Thall, PF; Valdez, BC	1
Alatrash, G; Alousi, AM; Anderlini, P; Bassett, R; Champlin, RE; Chen, J; Daher, M; Hosing, C; Kawedia, J; Kebriaei, P; Ledesma, C; Lu, Y; Marin, D; Mehta, R; Nieto, Y; Olson, A; Oran, B; Popat, U; Qazilbash, M; Rondon, G; Saberian, C; Shpall, EJ; Thall, PF; Valdez, BC	1
Carulli, A; Catania, C; Connor, MP; Frey, NV; Freyer, CW; Gill, SI; Hexner, EO; Hollander, L; Loren, AW; Luger, SM; Mangan, JK; Martin, ME; McCurdy, SR; Perl, AE; Porter, DL; Pratz, KW; Smith, J; Stadtmauer, EA; Timlin, C; Zebrowski, AM	1
Baruchel, A; Boëlle-Le Corfec, E; Geffriaud-Ricouard, C; Goto, H; Jeha, S; Pieters, R; Shin, HY	1
Akhter, N; Altman, JK; Canaani, J; Cascino, GJ; Foran, JM; Furiasse, N; Ky, B; Litzow, MR; Luger, S; Rademaker, A; Rigolin, V; Tallman, MS; Voss, WB	1
Hosono, N; Negoro, E; Nishi, R; Okura, M; Shigemi, H; Yamauchi, T	1
Dykes, J; Håkansson, Y; Król, L; Pronk, C; Toporski, J; Turkiewicz, D	1
Cloos, J; Hanekamp, D; Janssen, JJWM; Ngai, LL; Ossenkoppele, GJ; van de Loosdrecht, A	1
Borthakur, G; Burger, J; Daver, N; DiNardo, CD; Estrov, Z; Ferrajoli, A; Garcia-Manero, G; Huang, X; Jabbour, E; Jain, N; Kadia, TM; Kanagal-Shamanna, R; Kantarjian, H; Konopleva, M; Pemmaraju, N; Pierce, S; Popat, U; Rausch, C; Ravandi, F; Verstovsek, S; Wang, X	1
Alakel, N; Bornhäuser, M; Büttner, B; Ehninger, G; Knoth, H; Kramer, M; Middeke, JM; Oertel, R; Platzbecker, U; Röllig, C; Schetelig, J; Seeling, A; Sockel, K; Stölzel, F; von Bonin, M	1
Benitez, LL; Frame, D; Gharibian, K; Mody, R; Mora, E	1
Borthakur, G; Brandt, M; Cortes, JE; Daver, NG; DiNardo, CD; Estrov, Z; Gandhi, V; Garcia-Manero, G; Huang, X; Jabbour, E; Jain, N; Kadia, TM; Kantarjian, H; Konopleva, M; O'Brien, SM; Pemmaraju, N; Plunkett, W; Ravandi, F; Sasaki, K; Short, NJ; Wierda, WG; Xiao, L	2
Abla, O; Boklan, J; DuBois, SG; Goldberg, J; Hijiya, N; Martin, A; Messinger, Y; Oesterheld, J; Weinstein, J	1
Damiani, D; Fanin, R; Michelutti, A; Tiribelli, M	1
Altuntaş, F; Ayyildiz, MO; Bekdemir, F; Çakar, MK; Dal, MS; Dogu, MH; Hacioglu, SK; Ilkkiliç, K; Karakus, A; Kaya, AH; Korkmaz, S; Merdin, A; Tekgündüz, E	1
Bates, J; Buhlinger, K; Deal, AM; Foster, MC; Jamieson, KJ; Muluneh, B; Van Deventer, HW; Zeidner, JF	1
Bixby, DL; Crouch, A; Marini, BL; Nachar, VR; Perissinotti, AJ; Scappaticci, GB; Talpaz, M; Uebel, JR; Vulaj, V	1
Bejanyan, N; Defor, T; Eckfeldt, C; He, F; Kurtzweil, A; Parker, S; Rashidi, A; Sapkota, S; Ustun, C; Warlick, E; Weisdorf, D	1
Claxton, D; Miki, K; Mineishi, S; Naik, S; Rakszawski, K; Shike, H; Wagner, H	1
Andreeff, M; Bueso-Ramos, C; Cortes, JE; Coyle, M; Daver, N; DiNardo, CD; Futreal, PA; Garcia-Manero, G; Gumbs, C; Issa, GC; Jabbour, E; Jorgensen, J; Kadia, T; Kantarjian, HM; Konopleva, M; Little, L; Morita, K; Patel, KP; Pemmaraju, N; Ravandi, F; Sasaki, K; Song, X; Takahashi, K; Thornton, R; Tippen, S; Wang, F; Wang, S; Yan, Y; Zhang, J	1
Ali, A; Burnett, AK; Cahalin, P; Freeman, S; Hills, RK; Hunter, A; Nielsen, OJ; Russell, NH; Thomas, IF	1
Becker, H; Döhner, H; Döhner, K; Fiedler, W; Gaidzik, VI; Ganser, A; Götze, KS; Greil, C; Heuser, M; Janning, M; Kebenko, M; Könecke, C; Krauter, J; Lübbert, M; Neuhaus, B; Papkalla, A; Paschka, P; Reimer, P; Schlenk, RF; Thol, F; Verbeek, M; Wattad, M	1
Barbour, M; Bujold, KE; Dandekar, S	1
Alary, AS; Bouscary, D; Deau, B; Fontenay, M; Hermine, O; Kosmider, O; Mondesir, J; Sibon, D; Suarez, F; Tamburini, J; Willems, L	1
Choi, J; Coustan-Smith, E; Degar, B; Heym, K; Inaba, H; Klco, J; Lacayo, NJ; McNeer, J; Pounds, S; Pui, CH; Raimondi, SC; Ribeiro, RC; Rubnitz, JE; Schiff, D; Taub, J; Triplett, B; Wang, L; Yeoh, AE	1
Stirrups, R	1
Cumpston, A; Kanate, AS; Vos, J; Walchack, R	1
Aleem, A; Algahtani, F; Almomen, A; Alsaleh, K; Anjum, F; Iqbal, Z	1
Ali, S; Bowen, D; Burnett, AK; Hills, RK; Hunter, AE; Knapper, S; McMullin, MF; Milligan, D; Russell, NH; Wheatley, K; Yin, J	1
Andreeff, M; Borthakur, G; Brandt, M; Choi, S; Cortes, J; Daver, N; Du, M; Estrov, Z; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Huang, X; Jabbour, E; Kadia, T; Kantarjian, H; Konopleva, M; Kornblau, S; Nazha, A; Pemmaraju, N; Ravandi, F	1
Bücklein, V; Engel, N; Fritsch, S; Hausmann, A; Hill, W; Hubmann, M; Ledderose, G; Prevalsek, D; Schulz, C; Stemmler, HJ; Tischer, J; Zoellner, AK	1
Block, AW; Deeb, G; Ford, LA; Greene, JD; Griffiths, EA; Sait, SN; Starostik, P; Tan, W; Thompson, JE; Vigil, CE; Wang, ES; Wetzler, M	1
Allen, SL; Chidella, S; Fishbane, S; Jhaveri, KD	1
Bergua, J; Carpio, C; Herrera, P; Martínez-Cuadrón, D; Montesinos, P; Moscardó, F; Oriol, A; Rodríguez-Veiga, R; Salamero, O; Sanz, J; Sanz, MA; Vidriales, B; Vives, S	1
Kobos, R; Renaud, T; Shukla, N; Steinherz, LJ; Steinherz, PG	1
Ando, K; Kakihana, K; Miyata, Y; Nagai, T; Ogura, M; Suzuki, T; Tabata, Y; Uchida, T; Yamauchi, T	1
Andersson, BS; Champlin, RE; Corn, P; Dominguez, JR; Li, Y; Song, G; Valdez, BC	1
Azzarà, A; Benedetti, E; Buda, G; Caracciolo, F; Carulli, G; Fontanelli, G; Galimberti, S; Orciuolo, E; Petrini, M; Rocco, M	1
Abboud, CN; Bernabe, N; Cashen, A; Dipersio, JF; Jacoby, MA; Luo, J; Martin, MG; Reineck, T; Stockerl-Goldstein, K; Uy, GL; Vij, R; Westervelt, P	1
Amadori, S; de Witte, T; Halkes, CJ; Karrasch, M; Marie, JP; Meert, L; Meloni, G; Muus, P; Rapion, J; Suciu, S; Vignetti, M; Willemze, R	1
Nishi, R; Shigemi, H; Ueda, T; Uzui, K; Yamauchi, T	1
Alonzo, TA; Cooper, TM; Gamis, AS; Gerbing, RB; Horton, TM; Loken, MR; Meshinchi, S; Perentesis, JP; Razzouk, BI; Taub, JW; Whitlock, JA	1
Wiernik, PH	1
Bolognia, J; Marks, P; Podoltsev, N; Zhang, B	1
Böhm, A; Bojic, M; Greinix, H; Hauswirth, A; Jaeger, U; Kalhs, P; Keil, F; Rabitsch, W; Schellongowski, P; Sliwa, T; Sperr, WR; Valent, P; Wöhrer, S; Worel, N	1
Bilger, K; Blaise, D; Chevallier, P; de La Tour, RP; Delaunay, J; El-Cheikh, J; Furst, S; Guillaume, T; Labopin, M; Lioure, B; Michallet, M; Milpied, N; Mohty, M; Moreau, P; Socié, G; Tabrizi, R; Vigouroux, S	1
Abbi, KK; Claxton, DF; Ehmann, WC; Rybka, W	1
Andersson, BS; Champlin, RE; Li, Y; Liu, Y; Song, G; Valdez, BC	1
Fozza, C	1
Abkowitz, JL; Appelbaum, FR; Becker, PS; Estey, EH; Forman, SJ; Gardner, KM; Hendrie, PC; Medeiros, BC; Othus, M; Pagel, JM; Parks, C; Scott, BL; Stein, AS; Walter, RB; Wood, BL	1
DeAngelo, DJ; McDonnell, AM; Roberts, DA; Steensma, DP; Stone, RM; Wadleigh, M	1
Andersson, BS; Champlin, RE; Ji, J; Li, Y; Liu, Y; Murray, D; Popat, U; Valdez, BC	1
Borthakur, G; Brandt, M; Burger, J; Cortes, J; Faderl, S; Feliu, J; Ferrajoli, A; Garcia-Manero, G; Huang, X; Jabbour, E; Kadia, TM; Kantarjian, H; Konopleva, M; Pierce, S; Ravandi, F; Wang, X	1
Becker, PS; Buckley, SA; Dean, C; Estey, EH; Gooley, TA; Hendrie, P; Mawad, R; Pagel, JM; Sandhu, V; Scott, BL; Smith, K; Walter, RB; Wood, BL	1
Aydınok, Y; Balkan, C; Karadaş, N; Kavaklı, K; Önder Siviş, Z; Yılmaz Karapınar, D	1
Einsele, H; Grigoleit, GU; Heuschmann, PU; Hupp, E; Kapp, M; Loeffler, C; Loeffler, J; Malzahn, U; Mielke, S; Stuhler, G	1
Alyea, E; Ballen, KK; Chen, YB; Cutler, C; Dey, BR; Driscoll, J; El-Jawahri, A; Ho, VT; Hunnewell, C; Li, S; McAfee, SL; Poliquin, C; Saylor, M; Soiffer, RJ; Spitzer, TR	1
Alakel, N; Bethge, W; Bitz, U; Bornhäuser, M; Bug, G; Büttner, B; Ehninger, G; Hänel, M; Herbst, R; Klein, S; Knoth, H; Kramer, M; Middeke, JM; Morgner, A; Parmentier, S; Platzbecker, U; Röllig, C; Rösler, W; Schäfer-Eckart, K; Schaich, M; Schetelig, J; Sockel, K; Stölzel, F; Stuhler, G; Thiede, C; von Bonin, M	1
Andreeff, M; Borthakur, G; Cortes, J; DiNardo, C; Estrov, Z; Garcia-Manero, G; Jabbour, E; Kadia, T; Kantarjian, H; Konopleva, M; Pierce, S; Ravandi, F; Takahashi, K	1
Chevallier, P; Françoise, M; Grain, A; Guillaume, T; Mohty, M; Rialland, F; Sirvent, A; Strullu, M	1
Appelbaum, FR; Becker, PS; Bernstein, ID; Cicconi, L; Dahlberg, A; Delaney, C; Estey, EH; Milano, F; Nicoud, I; Othus, M; Sandhu, V	1
Alatrash, G; Alousi, AM; Andersson, BS; Champlin, RE; Chen, J; de Lima, M; Fox, PS; Garber, HR; Hosing, C; Janbey, S; Jones, RB; Kebriaei, P; Ning, J; Popat, U; Rondon, G; Shpall, EJ; Thall, PF; Valdez, BC; Worth, LL	1
Becker, PS; Braun, T; Churay, T; Eapen, M; Forman, S; Frey, N; Hari, P; Jagasia, M; Khaled, S; Kim, DD; Lieland, S; Logan, B; Magenau, J; McGuirk, J; Mineishi, S; Parkin, B; Rowley, SD; Schechter, T; Scott, B; Wang, H; Westervelt, P	1
Ali, S; Burnett, AK; Burns, S; Cahalin, P; Clark, RE; Dennis, M; Freeman, S; Hills, RK; Kell, J; Milligan, D; Nielsen, OJ; Pocock, C; Russell, NH	1
Bay, JO; Beckerich, F; Blaise, D; Bourhis, JH; Bulabois, CE; Chevallier, P; Contentin, N; Daguindau, E; de La Tour, RP; Delage, J; Detrait, M; François, S; Guillaume, T; Guillerm, G; Huynh, A; Labopin, M; Legrand, F; Lioure, B; Maillard, N; Mohty, M; Turlure, P; Vigouroux, S; Yakoub-Agha, I	1
Amadori, S; Baron, F; de Witte, T; Halkes, CJ; Marie, JP; Meert, L; Meloni, G; Muus, P; Pruijt, H; Ramadan, SM; Selleslag, D; Suciu, S; Venditti, A; Vignetti, M; Willemze, R; Wittnebel, S	1
Cairoli, R; Greco, R; Grillo, G; Mancini, V; Marbello, L; Molteni, A; Ravano, E; Riva, M; Zucchetti, E	1
Berthon, C; Cahn, JY; Caillot, D; Castaigne, S; Celli-Lebras, K; Chevret, S; de Botton, S; Dombret, H; Hermine, O; Ifrah, N; Lemasle, E; Marolleau, JP; Pigneux, A; Preudhomme, C; Raffoux, E; Recher, C; Reman, O; Simon, M; Terré, C; Thomas, X; Vey, N	1
Brower, V	1
Borthakur, G; Estrov, Z; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Huang, X; Kantarjian, HM; Kwari, M; Ravandi, F; Thomas, DA; Verstovsek, S	1
Estey, E	1
Borthakur, G; Estrov, Z; Faderl, S; Ferrajoli, A; Huang, X; Kantarjian, HM; Kwari, M; Ravandi, F; Verstovsek, S; Wierda, W	1
Ferrara, F; Musto, P	1
Abboud, CN; Augustin, K; Cashen, A; DiPersio, JF; Luo, J; Martin, MG; Procknow, E; Stockerl-Goldstein, K; Uy, GL; Vij, R; Westervelt, P	1
Gore, SD	1
Tallman, M	1
Vij, R	1
Larson, ML; Venugopal, P	1
Capria, S; Cardarelli, L; Foà, R; Matturro, A; Meloni, G; Santini, L; Trisolini, SM	1
Abichandani, R; Barry, E; Carroll, WL; Chu, R; Cooper, T; Gaynon, P; Hijiya, N; Jeha, S; Kadota, R; Rytting, M; Shen, V; Silverman, L; Steinherz, P; Thomson, B	1
Ansar, N; Hayad, A; Hayden, P; Krawczyk, J; MacDonagh, B; Meenaghan, T; Murphy, T; Murray, M; O'Dwyer, M; Swords, R	1
Cannas, G; Dombret, H; Elhamri, M; Lobe, I; Raffoux, E; Thomas, X	1
Grundy, M; Pallis, M; Pimblett, H; Ronan, J; Russell, N; Seedhouse, C; Shang, S	1
Abichandani, R; Arellano, M; Claxton, D; Craig, M; Douer, D; Eckert, S; Erba, HP; Faderl, S; Gabrilove, J; Kantarjian, HM; Kovascovics, T; Lyons, RM; Maris, M; Petersdorf, S; Shami, PJ; Yeager, AM	1
Kobos, R; Shukla, N; Steinherz, L; Steinherz, PG	1
Artz, A; Locke, FL; Rich, E; Stock, W; van Besien, K; Zhang, Y	1
Kobos, R; Latcha, S; Shukla, N; Steinherz, PG	1
Burnett, AK; Carr, R; Clark, R; Culligan, D; Das-Gupta, E; Dennis, M; Hills, RK; Hunter, A; Johnston, P; Kell, J; McMullin, MF; Milligan, D; Murphy, J; Paolini, S; Russell, NH; Yin, J	1
Cutlan, JE; Geddes, ER; Hymes, SR; Polder, K; Torres-Cabala, CA	1
Andersson, BS; Champlin, RE; Li, Y; Murray, D; Valdez, BC	1
Alousi, A; Andersson, BS; Champlin, RE; de Lima, M; Hosing, C; Jones, RB; Kebriaei, P; Madden, T; Popat, U; Rondon, G; Shpall, EJ; Thall, PF; Valdez, BC; Wang, X; Worth, LL	1
Czemerska, M; Grzybowska-Izydorczyk, O; Pluta, A; Robak, T; Szmigielska-Kapłon, A; Wierzbowska, A; Wolska, A	1
Abonour, R; Baute, J; Cox, E; Farag, SS; Jones, DR; Kane, K; Nelson, RP; Robertson, MJ; Schwartz, JE; Secrest, A; Srivastava, S; Sullivan, C; Wood, LL	1
Agura, E; Berryman, RB; Cooper, B; Fay, J; Holmes, H; Li, S; Maisel, C; Saracino, G; Tadic-Ovcina, M; Vance, E	1
Baer, MR; Gojo, I	1
Kwong, YL; Lee, HK; Leung, AY; Liu, HS; Sim, J; Tse, E; Yip, SF	1
Appelbaum, FR; Becker, P; Estey, E; Hendrie, P; Knoebel, RW; McQuary, A; Petersdorf, S	1
Bautista, F; Del Mar Andres, M; Fernandez-Navarro, JM; Moreno, L; Tasso, M; Verdeguer, A	1
Burnett, AK; Hills, RK	1
Baker, SD; Campana, D; Christensen, R; Coustan-Smith, E; Furmanski, BD; Heym, KM; Inaba, H; Li, L; Mascara, GP; Onciu, M; Pounds, SB; Pui, CH; Ribeiro, RC; Rubnitz, JE; Shurtleff, SA	1
Chen, R; Conrad, J; Dagis, A; Delioukina, M; Forman, SJ; Frankel, P; Kirschbaum, MH; Lacey, SF; Nademanee, A; Nakamura, R; Popplewell, L; Snyder, D; Stein, AS	1
Bolaños-Meade, J; Villela, L	1
Arellano, M; Claxton, D; Erba, HP; Faderl, S; Gabrilove, J; Gandhi, PJ; Huebner, D; Kantarjian, H; Kovacsovics, T; Lyons, RM	1
Beutel, G; Buchholz, S; Dammann, E; Eder, M; Ganser, A; Krauter, J; Stadler, M; Trummer, A	1
Buresova, L; Dvorakova, D; Jeziskova, I; Mayer, J; Racil, Z; Razga, F; Timilsina, S; Toskova, M	1
Artz, AS; Del Cerro, P; Godley, LA; Kline, J; Larson, RA; Nguyen, V; O'Donnell, PH; Odenike, O; Rich, E; Stock, W; van Besien, K	1
Amadori, S; Ammatuna, E; Annino, L; Chiarini, F; Cilloni, D; Di Raimondo, F; Fazi, P; Fozza, C; La Sala, E; Lunghi, M; Martelli, AM; Martinelli, G; Meloni, G; Pagano, L; Pane, F; Ricci, F; Rossetti, E; Stasi, R; Venditti, A; Vignetti, M	1
Tran, H; Yang, D	1
Borthakur, G; Burger, J; Faderl, S; Feliu, J; Ferrajoli, A; Garcia-Manero, G; Huang, X; Jabbour, E; Kadia, T; Kantarjian, HM; Konopleva, M; Ravandi, F; Wang, X	1
Buck, SA; Edwards, H; Ge, Y; Lograsso, SB; Matherly, LH; Taub, JW; Xie, C	1
Cesano, A; Cohen, A; Cordeiro, JA; Hawtin, RE; Hogge, D; Lacayo, N; Rosen, DB	1
Avigan, D; Collins, R; Craig, M; Faderl, S; Ganguly, S; Goldberg, S; Greiner, J; Hari, P; Huebner, D; Jagasia, M; Kantarjian, HM; Kovacsovics, T; Maris, M; Ravandi, F; Recher, C; Rizzieri, D; Schiller, G; Seiter, K; Stuart, R; Vasconcelles, M; Vey, N; Wang, ES; Wetzler, M	1
Carraway, HE; Gladstone, DE; Gore, SD; Greer, JM; Karp, JE; Levis, MJ; McDevitt, MA; Pratz, KW; Ricklis, RM; Showel, MM; Smith, BD; Yun, HD; Zeidan, AM	1
Buchholz, S; Chevallier, P; Ciceri, F; Faul, C; Finke, J; Ganser, A; Guillerm, G; Huynh, A; Kolb, HJ; Labopin, M; Lioure, B; Mohty, M; Nagler, A; Polge, E; Schubert, J	1
Goozner, M	1
Appelbaum, FR; Becker, PS; Estey, EH; Faderl, S; Kantarjian, HM; Pierce, S; Shan, J; Storer, B	1
Burnett, AK; Craddock, CF; Dufva, IH; Freeman, S; Hills, RK; Hunter, AE; Kell, J; Kjeldsen, L; Milligan, D; Russell, NH; Wheatley, K; Yin, J	1
Abd Elmoneim, A; Arceci, RJ; Boklan, J; Cooper, T; Gore, L; Narendran, A; Ricklis, RM; Rolla, K; Scott, T	1
Hwang, YY; Kwong, YL; Trendell-Smith, NJ; Yeung, CK	1
Ghanem, H; Jabbour, E; Kantarjian, H; Ohanian, M	1
Ahmed, AB; Bruserud, O; Hatfield, KJ; Kittang, AO; Reikvam, H; Sjo, M; Tvedt, TH	1
Angelucci, E; Biagiotti, C; Borin, L; Bosi, A; Caracciolo, F; Cutini, I; Fanci, R; Gianfaldoni, G; Longo, G; Mannelli, F; Pogliani, EM; Romani, C; Scappini, B; Simonetti, F; Susini, MC	1
Szer, J	1
Amadori, S; Bressanin, D; Cappellini, A; Chiarini, F; Falconi, M; Iacobucci, I; Lonetti, A; Martelli, AM; Martinelli, G; McCubrey, JA; Ognibene, A; Orsini, E; Pagliaro, P; Ricci, F; Tazzari, PL; Teti, G	1
Borthakur, G; Cortes, JE; Faderl, S; Garcia-Manero, G; Jabbour, E; Kantarjian, H; Mathisen, MS; Quintás-Cardama, A; Ravandi, F	1
Cortes, J; Du, M; Faderl, S; Gandhi, V; Giles, F; Ibrahim, N; Jeha, S; Kantarjian, HM; Keating, M; Khuri, F; Kozuch, P; McLaughlin, P; O'Brien, S; Plunkett, W; Rios, MB	1
Cortes, J; Craig, A; Davis, J; Du, M; Faderl, S; Freireich, EJ; Gandhi, V; Garcia-Manero, G; Giles, F; Jeha, S; Kantarjian, H; Keating, M; O'Brien, S; Plunkett, W; Shaked, Z; Verstovsek, S	1
Brandt, M; Chan, KW; Gandhi, V; Jeha, S; Kantarjian, H; Keating, M; Madden, R; McDonald, L; Plunkett, W; Ramirez, I; Rytting, M	1
Ayres, M; Bonate, P; Du, M; Faderl, S; Gandhi, V; Kantarjian, H; Keating, MJ; Plunkett, W; Rios, MB	1
Craig, AR; Douer, D; Levine, AM; Marshall, LC; Watkins, K; Weiss, JM	1
Bonate, PL; Craig, A; Gandhi, V; Gaynon, P; Jeha, S; Kadota, R; Lam, GN; Plunkett, W; Razzouk, B; Rytting, M; Steinherz, P; Weitman, S	1
Cooper, T; Gandhi, V; Kantarjian, H; Plunkett, W	1
Kline, JP; Larson, RA	1
Arthaud, L; Bonate, PL; Cantrell, WR; Secrist, JA; Stephenson, K; Weitman, S	1
Higgins, EM; Mufti, GJ; Powell, S; Salisbury, JR; Williams, JS	1
Faderl, S; Gandhi, V; Jeha, S; Kantarjian, HM; Wess, M	1
Faderl, S; Gandhi, V; Kantarjian, HM	1
Craig, CM; Schiller, GJ	1
Albertioni, F; Eriksson, S; Liliemark, J; Lotfi, K; Månsson, E; Peterson, C; Pettersson, B; Spasokoukotskaja, T	1

Reviews

19 review(s) available for clofarabine and Leukemia, Myeloid, Acute

Article	Year
Patient-Level Meta-analysis of Clofarabine in Acute Lymphoblastic Leukemia. Advances in therapy, 2023, Volume: 40, Issue:12 Topics: Acute Disease; Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Child; Clinical Trials, Phase II as Topic; Clofarabine; Humans; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence	2023
Optimal therapy for adult patients with acute myeloid leukemia in first complete remission. Current treatment options in oncology, 2014, Volume: 15, Issue:2 Topics: Adenine Nucleotides; Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Arabinonucleosides; Clofarabine; Cytarabine; Dose-Response Relationship, Drug; Humans; Interleukin-2; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction; Stem Cell Transplantation; Thalidomide; Treatment Outcome; Young Adult	2014
The role of Clofarabine in the treatment of adults with acute myeloid leukemia. Critical reviews in oncology/hematology, 2015, Volume: 93, Issue:3 Topics: Adenine Nucleotides; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clinical Trials as Topic; Clofarabine; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Remission Induction; Treatment Outcome	2015
Hypertension and Life-Threatening Bleeding in Children with Relapsed Acute Myeloblastic Leukemia Treated with FLT3 Inhibitors. Turkish journal of haematology : official journal of Turkish Society of Haematology, 2015, Volume: 32, Issue:3 Topics: Acidosis; Acute Kidney Injury; Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Child; Child, Preschool; Clofarabine; Cytarabine; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Hemorrhage; Humans; Hypertension; Indoles; Leukemia, Myeloid, Acute; Male; Neoplasm Proteins; Niacinamide; Pain; Pancytopenia; Phenylurea Compounds; Protease Inhibitors; Pyrroles; Salvage Therapy; Sepsis; Sorafenib; Sunitinib	2015
New drugs in acute myeloid leukemia. Seminars in oncology, 2008, Volume: 35, Issue:4 Topics: Adenine Nucleotides; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Azacitidine; Clofarabine; Decitabine; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Gemtuzumab; Humans; Leukemia, Myeloid, Acute	2008
Clofarabine: in search of combinations for the treatment of patients with high-risk acute myeloid leukemia. Cancer, 2008, Oct-15, Volume: 113, Issue:8 Topics: Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clinical Trials as Topic; Clofarabine; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local	2008
Clofarabine: a new treatment option for patients with acute myeloid leukemia. Expert opinion on pharmacotherapy, 2009, Volume: 10, Issue:8 Topics: Adenine Nucleotides; Adult; Antineoplastic Agents; Arabinonucleosides; Clofarabine; Humans; Leukemia, Myeloid, Acute	2009
Clofarabine for the treatment of adult acute myeloid leukemia. Future oncology (London, England), 2009, Volume: 5, Issue:8 Topics: Adenine Nucleotides; Adult; Aged; Animals; Antineoplastic Agents; Arabinonucleosides; Child; Clinical Trials as Topic; Clofarabine; Humans; Leukemia, Myeloid, Acute	2009
Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity. Current medicinal chemistry, 2011, Volume: 18, Issue:5 Topics: Adenine Nucleotides; Animals; Arabinonucleosides; Azacitidine; Benzamides; Clofarabine; Cytarabine; Cytosine; Daunorubicin; Decitabine; Dioxolanes; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Hydrazines; Imatinib Mesylate; Leukemia, Myeloid, Acute; Liposomes; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; TOR Serine-Threonine Kinases; Valproic Acid; Vascular Endothelial Growth Factor Receptor-1	2011
Acute myeloid leukaemia: optimal management and recent developments. Drugs, 2011, Aug-20, Volume: 71, Issue:12 Topics: Adenine Nucleotides; Antibodies, Monoclonal; Antineoplastic Agents; Arabinonucleosides; Clofarabine; Daunorubicin; Flavonoids; Humans; Leukemia, Myeloid, Acute; Piperidines	2011
Clofarabine in the treatment of newly diagnosed acute myeloid leukemia in older adults. The Annals of pharmacotherapy, 2012, Volume: 46, Issue:1 Topics: Adenine Nucleotides; Aged; Antineoplastic Agents; Arabinonucleosides; Clinical Trials as Topic; Clofarabine; Disease-Free Survival; Humans; Leukemia, Myeloid, Acute; Middle Aged; Treatment Outcome	2012
The role of clofarabine in acute myeloid leukemia. Leukemia & lymphoma, 2013, Volume: 54, Issue:4 Topics: Adenine Nucleotides; Age Factors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Drug Evaluation, Preclinical; Humans; Leukemia, Myeloid, Acute	2013
High-dose etoposide in allogeneic stem cell transplantation. Cancer chemotherapy and pharmacology, 2012, Volume: 70, Issue:6 Topics: Adenine Nucleotides; Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Busulfan; Carboplatin; Carmustine; Clinical Trials as Topic; Clofarabine; Cyclophosphamide; Dose Fractionation, Radiation; Drug Administration Schedule; Etoposide; Humans; Ifosfamide; Leukemia; Leukemia, Myeloid, Acute; Lomustine; Mucositis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiotherapy, Adjuvant; Severity of Illness Index; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation	2012
The prevalent predicament of relapsed acute myeloid leukemia. Hematology. American Society of Hematology. Education Program, 2012, Volume: 2012 Topics: Adenine Nucleotides; Adult; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Arabinonucleosides; Clinical Trials as Topic; Clofarabine; Decision Making; DNA Methylation; fms-Like Tyrosine Kinase 3; Gemtuzumab; Glycine; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Recurrence; Remission Induction; Risk Factors; Salvage Therapy; Stem Cell Transplantation; TOR Serine-Threonine Kinases; Transplantation, Homologous	2012
Clofarabine in the treatment of acute myeloid leukaemia and acute lymphoblastic leukaemia: a review. Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:15 Topics: Adenine Nucleotides; Arabinonucleosides; Clofarabine; Humans; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma	2005
Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nature reviews. Drug discovery, 2006, Volume: 5, Issue:10 Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Clinical Trials as Topic; Clofarabine; Drug Approval; Drug Design; Humans; Leukemia, Myeloid, Acute; Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma	2006
Clofarabine: past, present, and future. Leukemia & lymphoma, 2007, Volume: 48, Issue:10 Topics: Adenine Nucleotides; Aged; Animals; Arabinonucleosides; Child; Clinical Trials as Topic; Clofarabine; DNA Damage; Drug Approval; Humans; Leukemia, Myeloid, Acute; Medical Oncology; Middle Aged; Models, Biological; Models, Chemical; Myelodysplastic Syndromes; Prognosis; Purines	2007
Potential role of novel nucleoside analogs in the treatment of acute myeloid leukemia. Current opinion in hematology, 2008, Volume: 15, Issue:2 Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Clinical Trials as Topic; Clofarabine; Cytosine; Dioxolanes; Humans; Leukemia, Myeloid, Acute; Nucleosides	2008
Acute myeloid leukemia in the elderly: conventional and novel treatment approaches. Blood reviews, 2008, Volume: 22, Issue:4 Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Arabinonucleosides; Arsenic Trioxide; Arsenicals; Azacitidine; Clofarabine; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Oxides; Recurrence; Sulfonamides	2008

Trials

60 trial(s) available for clofarabine and Leukemia, Myeloid, Acute

Article	Year
The added value of multi-state modelling in a randomized controlled trial: The HOVON 102 study re-analyzed. Cancer medicine, 2022, Volume: 11, Issue:3 Topics: Clofarabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Recurrence; Remission Induction; Treatment Outcome	2022
A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial. British journal of haematology, 2022, Volume: 198, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Clofarabine; Cytarabine; Daunorubicin; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; United Kingdom; Vidarabine	2022
A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation. Bone marrow transplantation, 2022, Volume: 57, Issue:8 Topics: Bayes Theorem; Busulfan; Clofarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Transplantation Conditioning; Vidarabine	2022
Vorinostat Combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-Term Study Outcomes. Transplantation and cellular therapy, 2022, Volume: 28, Issue:8 Topics: Acute Disease; Busulfan; Clofarabine; Drug Therapy, Combination; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Recurrence; Vidarabine; Vorinostat	2022
Two-dimensional speckle-tracking strain detects subclinical cardiotoxicity in older patients treated for acute myeloid leukemia. Echocardiography (Mount Kisco, N.Y.), 2019, Volume: 36, Issue:11 Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Cardiotoxicity; Clofarabine; Cytarabine; Daunorubicin; Echocardiography; Female; Follow-Up Studies; Heart Ventricles; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Retrospective Studies; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left	2019
The combination of clofarabine, etoposide, and cyclophosphamide shows limited efficacy as a bridge to transplant for children with refractory acute leukemia: results of a monitored prospective study. Pediatric hematology and oncology, 2021, Volume: 38, Issue:3 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Clofarabine; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Treatment Outcome; Young Adult	2021
Early assessment of clofarabine effectiveness based on measurable residual disease, including AML stem cells. Blood, 2021, 03-25, Volume: 137, Issue:12 Topics: Antimetabolites, Antineoplastic; Clofarabine; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Neoplasm, Residual; Neoplastic Stem Cells; Treatment Outcome	2021
A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer, 2017, Nov-15, Volume: 123, Issue:22 Topics: Adenine Nucleotides; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Neoadjuvant Therapy; Treatment Outcome; Vidarabine; Young Adult	2017
A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leukemia & lymphoma, 2018, Volume: 59, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Clofarabine; Cytarabine; Drug Resistance, Neoplasm; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine; Young Adult	2018
Combination of clofarabine, cyclophosphamide, and etoposide for relapsed or refractory childhood and adolescent acute myeloid leukemia. Pediatric hematology and oncology, 2017, Volume: 34, Issue:4 Topics: Adenine Nucleotides; Adolescent; Adult; Allografts; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Child; Child, Preschool; Clofarabine; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid, Acute; Male; Survival Rate	2017
Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial). British journal of haematology, 2018, Volume: 183, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clofarabine; Cytarabine; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Remission Induction	2018
Clofarabine Can Replace Anthracyclines and Etoposide in Remission Induction Therapy for Childhood Acute Myeloid Leukemia: The AML08 Multicenter, Randomized Phase III Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 08-10, Volume: 37, Issue:23 Topics: Adolescent; Adult; Anthracyclines; Child; Child, Preschool; Clofarabine; Etoposide; Female; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Remission Induction; Young Adult	2019
Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood, 2013, Aug-22, Volume: 122, Issue:8 Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antineoplastic Agents; Arabinonucleosides; Clofarabine; Cytarabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Proportional Hazards Models; Remission Induction; Treatment Outcome	2013
Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia. American journal of hematology, 2013, Volume: 88, Issue:11 Topics: Adenine Nucleotides; Adult; Age Factors; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Consolidation Chemotherapy; Cytarabine; Drug Eruptions; Follow-Up Studies; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Middle Aged; Nausea; Pilot Projects; Remission Induction; Survival Analysis; Young Adult	2013
Phase II trial of clofarabine and daunorubicin as induction therapy for acute myeloid leukemia patients greater than or equal to 60 years of age. Leukemia research, 2013, Volume: 37, Issue:11 Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Staging; Prognosis; Remission Induction; Survival Rate	2013
Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia. Annals of hematology, 2014, Volume: 93, Issue:1 Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Comorbidity; Cytarabine; Drug Eruptions; Female; Humans; Leukemia, Myeloid, Acute; Liver Failure; Male; Mucositis; Prospective Studies; Remission Induction	2014
Phase II trial of clofarabine with topotecan, vinorelbine, and thiotepa in pediatric patients with relapsed or refractory acute leukemia. Pediatric blood & cancer, 2014, Volume: 61, Issue:3 Topics: Adenine Nucleotides; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Child; Child, Preschool; Clofarabine; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Thiotepa; Topotecan; Vinblastine; Vinorelbine	2014
Phase I study of clofarabine in adult patients with acute myeloid leukemia in Japan. Japanese journal of clinical oncology, 2013, Volume: 43, Issue:12 Topics: Adenine Nucleotides; Aged; Alanine Transaminase; Amylases; Antimetabolites, Antineoplastic; Arabinonucleosides; Asian People; Bone Marrow; Clofarabine; Drug Administration Schedule; Female; Humans; Japan; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Remission Induction; Treatment Outcome	2013
Phase I study of oral clofarabine consolidation in adults aged 60 and older with acute myeloid leukemia. American journal of hematology, 2014, Volume: 89, Issue:5 Topics: Adenine Nucleotides; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Arabinonucleosides; Clofarabine; Cohort Studies; Consolidation Chemotherapy; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged	2014
Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): p Annals of hematology, 2014, Volume: 93, Issue:6 Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Consolidation Chemotherapy; Cytarabine; Fatigue; Female; Gastrointestinal Diseases; Humans; Hydroxyurea; Hyperbilirubinemia; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Risk; Treatment Outcome	2014
AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia. Cancer, 2014, Aug-15, Volume: 120, Issue:16 Topics: Adenine Nucleotides; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Child; Child, Preschool; Clofarabine; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Male; Young Adult	2014
Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial. Haematologica, 2014, Volume: 99, Issue:9 Topics: Adenine Nucleotides; Adult; Aged; Antilymphocyte Serum; Arabinonucleosides; Busulfan; Clofarabine; Drug Administration Schedule; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Biphenotypic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous	2014
Phase I/II study of clofarabine, etoposide, and mitoxantrone in patients with refractory or relapsed acute leukemia. Clinical lymphoma, myeloma & leukemia, 2015, Volume: 15, Issue:1 Topics: Adenine Nucleotides; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Recurrence; Remission Induction; Treatment Outcome	2015
G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm. American journal of hematology, 2015, Volume: 90, Issue:4 Topics: Adenine Nucleotides; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Young Adult	2015
Low efficacy and high mortality associated with clofarabine treatment of relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes. Leukemia research, 2015, Volume: 39, Issue:2 Topics: Adenine Nucleotides; Adult; Aged; Antimetabolites, Antineoplastic; Arabinonucleosides; Clofarabine; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Risk Factors; Survival Rate; Time Factors	2015
Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. Cancer, 2015, Jul-15, Volume: 121, Issue:14 Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Azacitidine; Clofarabine; Cytarabine; Decitabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Nausea; Remission Induction; Treatment Outcome	2015
A phase I/II study of oral clofarabine plus low-dose cytarabine in previously treated acute myeloid leukaemia and high-risk myelodysplastic syndrome patients at least 60 years of age. British journal of haematology, 2015, Volume: 170, Issue:3 Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Survival Rate	2015
Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Acute Lymphoid Leukemia. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:1 Topics: Adenine Nucleotides; Adult; Aged; Arabinonucleosides; Busulfan; Chronic Disease; Clofarabine; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Transplantation Conditioning	2016
Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial. Leukemia, 2016, Volume: 30, Issue:2 Topics: Adenine Nucleotides; Adult; Aged; Antimetabolites, Antineoplastic; Arabinonucleosides; Clofarabine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Recurrence; Salvage Therapy; Transplantation, Homologous	2016
Infusion of a non-HLA-matched ex-vivo expanded cord blood progenitor cell product after intensive acute myeloid leukaemia chemotherapy: a phase 1 trial. The Lancet. Haematology, 2016, Volume: 3, Issue:7 Topics: Adenine Nucleotides; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cohort Studies; Cord Blood Stem Cell Transplantation; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Staging; Young Adult	2016
A multicenter trial of myeloablative clofarabine and busulfan conditioning for relapsed or primary induction failure AML not in remission at the time of allogeneic hematopoietic stem cell transplantation. Bone marrow transplantation, 2017, Volume: 52, Issue:1 Topics: Adenine Nucleotides; Adult; Aged; Allografts; Arabinonucleosides; Busulfan; Clofarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate; Transplantation Conditioning	2017
Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: combined phase I/II results of the EORTC Haematologica, 2017, Volume: 102, Issue:2 Topics: Adenine Nucleotides; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Drug Administration Schedule; Female; Gene Expression; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Oncogene Proteins, Fusion; Random Allocation; Remission Induction; Risk Factors; Survival Analysis; Transplantation, Homologous; Treatment Outcome	2017
Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Apr-10, Volume: 35, Issue:11 Topics: Adenine Nucleotides; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Consolidation Chemotherapy; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome	2017
A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood, 2008, Sep-01, Volume: 112, Issue:5 Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Chromosome Aberrations; Clofarabine; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Survival Rate	2008
Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer, 2008, Oct-15, Volume: 113, Issue:8 Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Middle Aged; Salvage Therapy	2008
Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG. Bone marrow transplantation, 2009, Volume: 44, Issue:1 Topics: Adenine Nucleotides; Adult; Aged; Antilymphocyte Serum; Antimetabolites, Antineoplastic; Arabinonucleosides; Clofarabine; Cytarabine; Disease-Free Survival; Female; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Stem Cell Transplantation; Survival Rate; Time Factors; Transplantation Conditioning; Transplantation, Homologous	2009
A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia. Leukemia, 2009, Volume: 23, Issue:12 Topics: Acute Disease; Adenine Nucleotides; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Clofarabine; Cyclophosphamide; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Salvage Therapy; Treatment Outcome; Young Adult	2009
Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Feb-01, Volume: 28, Issue:4 Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antineoplastic Agents; Arabinonucleosides; Clofarabine; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Remission Induction; Survival Rate; Treatment Outcome	2010
European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, May-10, Volume: 28, Issue:14 Topics: Adenine Nucleotides; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Arabinonucleosides; Chi-Square Distribution; Clofarabine; Feasibility Studies; Female; Humans; Italy; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Medication Adherence; Middle Aged; Odds Ratio; Patient Selection; Proportional Hazards Models; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; United Kingdom	2010
Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:6 Topics: Adenine Nucleotides; Animals; Antilymphocyte Serum; Antineoplastic Agents; Arabinonucleosides; Busulfan; Cell Line, Tumor; Clofarabine; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Rabbits; Remission Induction; Survival Analysis; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Vidarabine	2011
Phase I trial and pharmacokinetic study of high-dose clofarabine and busulfan and allogeneic stem cell transplantation in adults with high-risk and refractory acute leukemia. Leukemia, 2011, Volume: 25, Issue:4 Topics: Adenine Nucleotides; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Busulfan; Clofarabine; Combined Modality Therapy; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Risk Factors; Stem Cell Transplantation; Survival Rate; Tissue Distribution; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Young Adult	2011
Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity. The oncologist, 2011, Volume: 16, Issue:2 Topics: Adenine Nucleotides; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Recurrence, Local; Patient Selection; Recurrence; Remission Induction; Survival Analysis; Treatment Outcome	2011
Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Aug-20, Volume: 29, Issue:24 Topics: Adenine Nucleotides; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Benzenesulfonates; Child; Clofarabine; Cytarabine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Leukemia; Leukemia, Myeloid, Acute; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Recurrence; Sorafenib	2011
A phase I study in adults of clofarabine combined with high-dose melphalan as reduced-intensity conditioning for allogeneic transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:3 Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous	2012
Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia. Leukemia & lymphoma, 2012, Volume: 53, Issue:3 Topics: Acute Kidney Injury; Adenine Nucleotides; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Arabinonucleosides; Clofarabine; Consolidation Chemotherapy; Drug Administration Schedule; Female; Gastrointestinal Diseases; Humans; Hypokalemia; Inpatients; Length of Stay; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Outpatients; Pneumonia; Quality of Life	2012
Cytoreductive treatment with clofarabine/ara-C combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with high-risk, relapsed, or refractory acute myeloid leukemia and advanced myelodysplastic syndrome. European journal of haematology, 2012, Volume: 88, Issue:1 Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cyclosporine; Cytarabine; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Mycophenolic Acid; Myelodysplastic Syndromes; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous	2012
Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:6 Topics: Acute Kidney Injury; Adenine Nucleotides; Adult; Age Factors; Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arabinonucleosides; Clofarabine; Female; Glomerular Filtration Rate; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Recurrence; Risk; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous	2012
Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107). British journal of haematology, 2012, Volume: 156, Issue:2 Topics: Adenine Nucleotides; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Salvage Therapy; Sirolimus; TOR Serine-Threonine Kinases	2012
Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer, 2012, Sep-15, Volume: 118, Issue:18 Topics: Adenine Nucleotides; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Azacitidine; Clofarabine; Consolidation Chemotherapy; Cytarabine; Decitabine; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome	2012
Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jul-10, Volume: 30, Issue:20 Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Placebos; Recurrence	2012
Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias. British journal of haematology, 2012, Volume: 158, Issue:2 Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Recurrence; Remission Induction; Salvage Therapy; Treatment Outcome; Young Adult	2012
Retrospective comparison of clofarabine versus fludarabine in combination with high-dose cytarabine with or without granulocyte colony-stimulating factor as salvage therapies for acute myeloid leukemia. Haematologica, 2013, Volume: 98, Issue:1 Topics: Adenine Nucleotides; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Middle Aged; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Vidarabine; Young Adult	2013
Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Nov-10, Volume: 30, Issue:32 Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Gemtuzumab; Humans; Immunotoxins; Incidence; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Odds Ratio; Remission Induction; Secondary Prevention; Treatment Outcome	2012
Phase I dose-escalation trial of clofarabine followed by escalating doses of fractionated cyclophosphamide in children with relapsed or refractory acute leukemias. Pediatric blood & cancer, 2012, Dec-15, Volume: 59, Issue:7 Topics: Acute Disease; Adenine Nucleotides; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Child; Child, Preschool; Clofarabine; Cyclophosphamide; DNA Damage; Drug Administration Schedule; Female; Humans; Leukemia; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Young Adult	2012
Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients. American journal of hematology, 2012, Volume: 87, Issue:12 Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Treatment Outcome; Young Adult	2012
Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Mar-15, Volume: 21, Issue:6 Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Agents; Arabinonucleosides; Bone Marrow; Breast Neoplasms; Clofarabine; Drug Administration Schedule; Female; Gastrointestinal Neoplasms; Hematologic Neoplasms; Humans; Infusions, Intravenous; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Liver; Lung Neoplasms; Male; Middle Aged; Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Treatment Outcome	2003
Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood, 2003, Oct-01, Volume: 102, Issue:7 Topics: Adenine Nucleotides; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arabinonucleosides; Clofarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Recurrence; Survival Rate; Treatment Outcome	2003
Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood, 2004, Feb-01, Volume: 103, Issue:3 Topics: Adenine Nucleotides; Adolescent; Adult; Antineoplastic Agents; Arabinonucleosides; Child; Child, Preschool; Clofarabine; DNA, Neoplasm; Drug Tolerance; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma	2004
Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Dec-15, Volume: 9, Issue:17 Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Clofarabine; DNA; Dose-Response Relationship, Drug; Humans; Leukemia; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Models, Chemical; Neoplastic Cells, Circulating; Oligonucleotides; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Time Factors	2003
Clofarabine in adult acute leukemias: clinical success and pharmacokinetics. Nucleosides, nucleotides & nucleic acids, 2004, Volume: 23, Issue:8-9 Topics: Adenine Nucleotides; Adult; Antimetabolites, Antineoplastic; Arabinonucleosides; Clinical Trials as Topic; Clofarabine; Cohort Studies; Cytarabine; Dose-Response Relationship, Drug; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Models, Chemical; Myelodysplastic Syndromes; Neoplasm Metastasis; Neoplasms; Nucleosides; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Treatment Outcome	2004

Other Studies

66 other study(ies) available for clofarabine and Leukemia, Myeloid, Acute

Article	Year
Clofarabine-fludarabine-busulfan in HCT for pediatric leukemia: an effective, low toxicity, TBI-free conditioning regimen. Blood advances, 2022, 03-22, Volume: 6, Issue:6 Topics: Busulfan; Child; Clofarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Recurrence; Vidarabine	2022
Successful clofarabine desensitization in a pediatric patient with acute myeloid leukemia. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2022, Volume: 33, Issue:1 Topics: Child; Clofarabine; Humans; Leukemia, Myeloid, Acute; Remission Induction	2022
Clofarabine with topotecan, vinorelbine, and thiotepa reinduction regimen for children and young adults with relapsed AML. Blood advances, 2022, 04-26, Volume: 6, Issue:8 Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Child; Clofarabine; Humans; Leukemia, Myeloid, Acute; Recurrence; Thiotepa; Topotecan; Vinorelbine; Young Adult	2022
Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies. Transplantation and cellular therapy, 2023, Volume: 29, Issue:2 Topics: Adult; Aged; Busulfan; Clofarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myeloablative Agonists; Myeloproliferative Disorders; Recurrence; Retrospective Studies; Transplantation, Homologous; Young Adult	2023
Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine. BMC cancer, 2020, Oct-12, Volume: 20, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cell Proliferation; Clofarabine; Cytarabine; Flavonoids; Humans; Leukemia, Myeloid, Acute; Piperidines; Sulfonamides	2020
Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. American journal of hematology, 2021, 08-01, Volume: 96, Issue:8 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Clofarabine; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Nucleophosmin; Treatment Outcome	2021
Impact of pharmacokinetics on the toxicity and efficacy of clofarabine in patients with relapsed or refractory acute myeloid leukemia. Leukemia & lymphoma, 2017, Volume: 58, Issue:12 Topics: Adenine Nucleotides; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Area Under Curve; Clofarabine; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; Liver; Liver Function Tests; Male; Middle Aged; Recurrence; Skin; Treatment Outcome	2017
Clofarabine Dosing in a Patient With Acute Myeloid Leukemia on Intermittent Hemodialysis: Case Report and Review of the Literature. Journal of pediatric hematology/oncology, 2017, Volume: 39, Issue:6 Topics: Adenine Nucleotides; Adult; Antimetabolites, Antineoplastic; Arabinonucleosides; Clofarabine; Humans; Leukemia, Myeloid, Acute; Male; Renal Dialysis; Young Adult	2017
ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia. Cancer, 2017, 12-15, Volume: 123, Issue:24 Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Clofarabine; Cytarabine; Deoxyadenosines; Humans; Idarubicin; Leukemia, Myeloid, Acute; Neoplasm Proteins; Vidarabine	2017
Efficacy of CLARA in recurrent/refractory acute myeloid leukaemia patients unresponsive to FLAG chemotherapy. Journal of chemotherapy (Florence, Italy), 2018, Volume: 30, Issue:1 Topics: Adenine Nucleotides; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Vidarabine; Young Adult	2018
A Comparison of Clofarabine-based (GCLAC) and Cladribine-based (CLAG) Salvage Chemotherapy for Relapsed/Refractory AML. Clinical lymphoma, myeloma & leukemia, 2018, Volume: 18, Issue:1 Topics: Cladribine; Clofarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Salvage Therapy	2018
Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG. Annals of hematology, 2018, Volume: 97, Issue:4 Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Aging; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Case-Control Studies; Chemical and Drug Induced Liver Injury; Clofarabine; Cohort Studies; Combined Modality Therapy; Cost Savings; Costs and Cost Analysis; Cytarabine; Granulocyte Colony-Stimulating Factor; Hospital Costs; Humans; Incidence; Induction Chemotherapy; Length of Stay; Leukemia, Myeloid, Acute; Michigan; Middle Aged; Neutropenia; Propensity Score; Retrospective Studies; Survival Analysis; Tertiary Care Centers; Vidarabine	2018
A real-world study of clofarabine and cytarabine combination therapy for patients with acute myeloid leukemia. Leukemia & lymphoma, 2018, Volume: 59, Issue:10 Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Clofarabine; Cytarabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Minnesota; Progression-Free Survival; Remission Induction; Retrospective Studies; Salvage Therapy	2018
Clofarabine followed by haploidentical stem cell transplant using fludarabine, busulfan, and total-body irradiation with post-transplant cyclophosphamide in non-remission AML. International journal of hematology, 2018, Volume: 108, Issue:3 Topics: Adenine Nucleotides; Adult; Arabinonucleosides; Busulfan; Clofarabine; Combined Modality Therapy; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Remission Induction; Transplantation Conditioning; Transplantation, Haploidentical; Treatment Outcome; Tumor Burden; Vidarabine	2018
Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018, 06-20, Volume: 36, Issue:18 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clofarabine; Cohort Studies; Cytarabine; DNA, Neoplasm; Female; High-Throughput Nucleotide Sequencing; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Recurrence; Sequence Analysis, DNA; Vidarabine	2018
A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial. Leukemia, 2018, Volume: 32, Issue:12 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Clofarabine; Cytarabine; Daunorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; United Kingdom; Vidarabine; Young Adult	2018
Successful Treatment of Relapsed Pediatric Acute Myeloid Leukemia Presenting as Central Nervous System Myeloid Sarcoma: A Single-Institution Case Series. Journal of pediatric hematology/oncology, 2020, Volume: 42, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Child, Preschool; Clofarabine; Female; Humans; Injections, Spinal; Leukemia, Myeloid, Acute; Sarcoma, Myeloid; Thiotepa; Topotecan; Vinorelbine	2020
Impact of genotype in relapsed and refractory acute myeloid leukaemia patients treated with clofarabine and cytarabine: a retrospective study. British journal of haematology, 2019, Volume: 187, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clofarabine; Cytarabine; Drug Administration Schedule; Female; Follow-Up Studies; Genotype; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Prognosis; Recurrence; Retrospective Studies; Salvage Therapy; Survival Analysis; Young Adult	2019
Clofarabine and cytarabine for acute myeloid leukaemia. The Lancet. Oncology, 2019, Volume: 20, Issue:8 Topics: Arabinonucleosides; Clofarabine; Cytarabine; Humans; Leukemia, Myeloid, Acute	2019
Delayed-onset effect of clofarabine in the treatment of an adult patient with acute myeloid leukemia. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2019, Feb-21, Volume: 76, Issue:6 Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Blood Cell Count; Bone Marrow; Clofarabine; Cytarabine; Filgrastim; Humans; Leukemia, Myeloid, Acute; Male; Remission Induction; Time Factors; Treatment Outcome	2019
Clofarabine in the treatment of elderly patients with acute myeloid leukemia. Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:2 Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Aging; Antimetabolites, Antineoplastic; Arabinonucleosides; Clofarabine; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Leukemia, Myeloid, Acute; Male; Neutropenia; Remission Induction; Retrospective Studies; Survival; Treatment Outcome	2013
Feasibility of clofarabine cytoreduction followed by haploidentical hematopoietic stem cell transplantation in patients with relapsed or refractory advanced acute leukemia. Annals of hematology, 2013, Volume: 92, Issue:10 Topics: Adenine Nucleotides; Adult; Aged; Arabinonucleosides; Clofarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Young Adult	2013
Clofarabine-induced kidney toxicity. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2014, Volume: 20, Issue:4 Topics: Acute Kidney Injury; Adenine Nucleotides; Animals; Arabinonucleosides; Clofarabine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Proteinuria	2014
The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan. Leukemia & lymphoma, 2014, Volume: 55, Issue:7 Topics: Adenine Nucleotides; Antineoplastic Agents, Alkylating; Apoptosis; Arabinonucleosides; Busulfan; Cell Line, Tumor; Cell Membrane Permeability; Cell Proliferation; Clofarabine; DNA Damage; DNA-Binding Proteins; Drug Combinations; Drug Resistance, Neoplasm; Drug Synergism; Histone Deacetylase Inhibitors; Histones; Humans; Leukemia, Myeloid, Acute; Mitochondria; Nuclear Proteins; Signal Transduction; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vidarabine	2014
Sorafenib as monotherapy or in association with cytarabine and clofarabine for the treatment of relapsed/refractory FLT3 ITD-positive advanced acute myeloid leukemia. Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:1 Topics: Adenine Nucleotides; Adult; Arabinonucleosides; Clofarabine; Cytarabine; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Tandem Repeat Sequences; Young Adult	2014
Cytarabine-resistant leukemia cells are moderately sensitive to clofarabine in vitro. Anticancer research, 2014, Volume: 34, Issue:4 Topics: Adenine Nucleotides; Antimetabolites, Antineoplastic; Apoptosis; Arabinonucleosides; Cell Line, Tumor; Cell Proliferation; Clofarabine; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; HL-60 Cells; Humans; Intracellular Space; Leukemia, Myeloid, Acute; Membrane Transport Proteins; Phosphotransferases (Alcohol Group Acceptor)	2014
Enhanced skin toxicity associated with the combination of clofarabine plus cytarabine for the treatment of acute leukemia. Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:2 Topics: Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Retrospective Studies; Skin Diseases	2014
Clofarabine/cyclophosphamide for debulking before stem cell transplantation. European journal of clinical investigation, 2014, Volume: 44, Issue:8 Topics: Adenine Nucleotides; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cyclophosphamide; Drug Administration Schedule; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Transplantation, Homologous; Treatment Outcome; Young Adult	2014
Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:11 Topics: Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arabinonucleosides; Busulfan; Clofarabine; DNA Damage; Drug Synergism; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Phosphorylation; Sorafenib; Tandem Repeat Sequences; Vidarabine	2014
Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: Enhancement of cytotoxicity with epigenetic modulators. Experimental hematology, 2015, Volume: 43, Issue:6 Topics: Adenine Nucleotides; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Ataxia Telangiectasia Mutated Proteins; Busulfan; Cell Line, Tumor; Cladribine; Clofarabine; Epigenesis, Genetic; Humans; Leukemia, Myeloid, Acute; Membrane Potential, Mitochondrial; Real-Time Polymerase Chain Reaction; Vidarabine	2015
Control of relapsed or refractory acute myeloid leukemia by clofarabine in preparation for allogeneic stem cell transplant. Leukemia & lymphoma, 2015, Volume: 56, Issue:12 Topics: Adenine Nucleotides; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Retreatment; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Young Adult	2015
Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients. Clinical lymphoma, myeloma & leukemia, 2016, Volume: 16, Issue:3 Topics: Adenine Nucleotides; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cohort Studies; Combined Modality Therapy; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retreatment; Treatment Outcome	2016
Sustained responses after clofarabine-based sequential allogeneic stem cell transplantation in children with high-risk, relapse and/or refractory acute myeloid leukemia or juvenile myelomonocytic leukemia: a study on behalf of the French society of bone m Leukemia & lymphoma, 2016, Volume: 57, Issue:12 Topics: Adenine Nucleotides; Adolescent; Arabinonucleosides; Child; Child, Preschool; Clofarabine; Combined Modality Therapy; Female; France; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Juvenile; Male; Recurrence; Retrospective Studies; Risk Factors; Transplantation, Homologous; Treatment Outcome; Young Adult	2016
Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:10 Topics: Adenine Nucleotides; Adolescent; Adult; Arabinonucleosides; Busulfan; Child; Clofarabine; Female; Graft Survival; Graft vs Host Disease; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult	2016
A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia. Leukemia, 2017, Volume: 31, Issue:2 Topics: Adenine Nucleotides; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Cause of Death; Clofarabine; Cytarabine; Daunorubicin; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Survival Analysis; Treatment Outcome	2017
Clofarabine versus fludarabine-based reduced-intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS. Cancer medicine, 2016, Volume: 5, Issue:11 Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult	2016
Clofarabine-based chemotherapy as a bridge to transplant in the setting of refractory or relapsed acute myeloid leukemia, after at least one previous unsuccessful salvage treatment containing fludarabine: a single institution experience. International journal of hematology, 2017, Volume: 105, Issue:6 Topics: Adenine Nucleotides; Adolescent; Adult; Aged; Allografts; Arabinonucleosides; Clofarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Retrospective Studies; Salvage Therapy; Vidarabine	2017
Clofarabine-based consolidation therapy in AML. The Lancet. Oncology, 2017, Volume: 18, Issue:4 Topics: Adenine Nucleotides; Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Consolidation Chemotherapy; Cytarabine; Disease Progression; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Young Adult	2017
New agents for the treatment of AML recent study findings. Clinical advances in hematology & oncology : H&O, 2008, Volume: 6, Issue:11 Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Carbazoles; Clofarabine; Decitabine; Enzyme Inhibitors; Furans; Humans; Hydrazines; Immunotherapy; Lenalidomide; Leukemia, Myeloid, Acute; Quinolones; Staurosporine; Sulfonamides; Thalidomide	2008
Existing and emerging therapeutic options for the treatment of acute myeloid leukemia. Clinical advances in hematology & oncology : H&O, 2008, Volume: 6, Issue:11 Topics: Adenine; Adenine Nucleotides; Aminoglycosides; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arabinonucleosides; Carbazoles; Clofarabine; Cytarabine; Dasatinib; Daunorubicin; fms-Like Tyrosine Kinase 3; Furans; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Naphthalimides; Organophosphonates; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Sesquiterpenes; Staurosporine; Stem Cell Transplantation; Thiazoles; Tretinoin	2008
Clofarabine: a size that fits all, may not fit all. Leukemia & lymphoma, 2009, Volume: 50, Issue:3 Topics: Adenine Nucleotides; Arabinonucleosides; Clofarabine; Drug Administration Schedule; Humans; Leukemia; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Treatment Outcome	2009
Acute myeloid leukemia and ischemic heart disease successful first line treatment with clofarabine as single agent. Leukemia research, 2009, Volume: 33, Issue:12 Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Clofarabine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myocardial Ischemia; Treatment Outcome	2009
Clofarabine in the treatment of poor risk acute myeloid leukaemia. Hematological oncology, 2010, Volume: 28, Issue:3 Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Risk Factors; Young Adult	2010
Impaired S-phase arrest in acute myeloid leukemia cells with a FLT3 internal tandem duplication treated with clofarabine. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Dec-01, Volume: 15, Issue:23 Topics: Adenine Nucleotides; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Cell Cycle; Cell Line, Tumor; Clofarabine; DNA Repair; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Leukemic; Histones; Humans; Leukemia, Myeloid, Acute; Mutation; Phenotype; S Phase; Tandem Repeat Sequences	2009
Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia. Pediatric blood & cancer, 2010, Volume: 54, Issue:5 Topics: Adenine Nucleotides; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Child; Child, Preschool; Clofarabine; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Salvage Therapy; Thiotepa; Topotecan; Vinblastine; Vinorelbine	2010
Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML. Bone marrow transplantation, 2010, Volume: 45, Issue:12 Topics: Adenine Nucleotides; Adolescent; Adult; Aged; Antineoplastic Agents; Arabinonucleosides; Clofarabine; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Transplantation Conditioning; Treatment Outcome; Young Adult	2010
Effect of hemodialysis on the plasma levels of clofarabine. Pediatric blood & cancer, 2010, Jul-15, Volume: 55, Issue:1 Topics: Acute Kidney Injury; Adenine Nucleotides; Arabinonucleosides; Clofarabine; Humans; Leukemia, Myeloid, Acute; Male; Renal Dialysis; Treatment Outcome; Young Adult	2010
Ulcerated plaque under a ruby ring in an immunosuppressed patient. Dermatology online journal, 2010, Aug-15, Volume: 16, Issue:8 Topics: Adenine Nucleotides; Aged; Antineoplastic Agents; Arabinonucleosides; Candida; Candidiasis, Cutaneous; Clofarabine; Cytarabine; Dermatologic Agents; Dermatomycoses; Fusarium; Humans; Immunocompromised Host; Itraconazole; Jewelry; Leukemia, Myeloid, Acute; Male; Pyrimidines; Skin Ulcer; Treatment Outcome; Triazoles; Voriconazole	2010
The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling. Biochemical pharmacology, 2011, Jan-15, Volume: 81, Issue:2 Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Ataxia Telangiectasia Mutated Proteins; Busulfan; Cell Cycle Proteins; Cell Line, Tumor; Clofarabine; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Therapy, Combination; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Protein Serine-Threonine Kinases; Tumor Suppressor Proteins; Vidarabine	2011
Novel agents for the treatment of acute myeloid leukemia in the older patient. Journal of the National Comprehensive Cancer Network : JNCCN, 2011, Volume: 9, Issue:3 Topics: Adenine Nucleotides; Age Factors; Aged; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Clofarabine; Cytosine; Decitabine; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Quinolones; Thalidomide	2011
Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia. Annals of hematology, 2011, Volume: 90, Issue:11 Topics: Adenine Nucleotides; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Treatment Outcome; Young Adult	2011
Infections in relapsed or refractory acute myeloid leukemia patients given clofarabine+cytarabine. Leukemia research, 2011, Volume: 35, Issue:9 Topics: Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Drug Resistance, Neoplasm; Humans; Infections; Leukemia, Myeloid, Acute; Recurrence; Treatment Failure	2011
Institutional experience with clofarabine and cytarabine in relapsed pediatric acute myeloid leukemia. Journal of pediatric hematology/oncology, 2012, Volume: 34, Issue:1 Topics: Adenine Nucleotides; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Child; Child, Preschool; Clofarabine; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid, Acute; Male; Recurrence; Retrospective Studies; Transplantation, Homologous	2012
Applicability of a "Pick a Winner" trial design to acute myeloid leukemia. Blood, 2011, Sep-01, Volume: 118, Issue:9 Topics: Adenine Nucleotides; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Arsenic Trioxide; Arsenicals; Clinical Trials, Phase III as Topic; Clofarabine; Cost-Benefit Analysis; Cytarabine; Cytosine; Drug Discovery; Early Termination of Clinical Trials; Follow-Up Studies; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Middle Aged; Multicenter Studies as Topic; Oxides; Patient Selection; Quality-Adjusted Life Years; Quinolones; Randomized Controlled Trials as Topic; Research Design; Sample Size; Software Design; Treatment Outcome; United Kingdom	2011
Treatment of molecular relapse in patients with acute myeloid leukemia using clofarabine monotherapy. American journal of hematology, 2012, Volume: 87, Issue:2 Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Agents; Arabinonucleosides; Clofarabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nuclear Proteins; Nucleophosmin; Oncogene Proteins, Fusion; Recurrence; Remission Induction; Survival Analysis; Treatment Outcome	2012
Valproic acid synergistically enhances the cytotoxicity of clofarabine in pediatric acute myeloid leukemia cells. Pediatric blood & cancer, 2012, Dec-15, Volume: 59, Issue:7 Topics: Adenine Nucleotides; Adolescent; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Cell Line, Tumor; Child; Child, Preschool; Clofarabine; Cytarabine; DNA Damage; Drug Screening Assays, Antitumor; Drug Synergism; Female; Histone Deacetylase Inhibitors; Humans; Infant; Leukemia, Myeloid, Acute; Male; Tumor Cells, Cultured; Valproic Acid	2012
Assessing signaling pathways associated with in vitro resistance to cytotoxic agents in AML. Leukemia research, 2012, Volume: 36, Issue:7 Topics: Adenine Nucleotides; Adolescent; Adult; Aged; Arabinonucleosides; Azacitidine; Child; Child, Preschool; Clofarabine; Cytotoxins; Decitabine; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Acute; Middle Aged; Models, Biological; Signal Transduction; Tumor Cells, Cultured	2012
Clofarabine-containing conditioning regimen for allo-SCT in AML/ALL patients: a survey from the Acute Leukemia Working Party of EBMT. European journal of haematology, 2012, Volume: 89, Issue:3 Topics: Adenine Nucleotides; Adolescent; Adult; Aged; Arabinonucleosides; Clofarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Young Adult	2012
Drug shortages delay cancer clinical trials. Journal of the National Cancer Institute, 2012, Jun-20, Volume: 104, Issue:12 Topics: Adenine Nucleotides; Aged; Antineoplastic Agents; Arabinonucleosides; Child; Clinical Trials as Topic; Clofarabine; Cytarabine; Daunorubicin; Drug Approval; Drug Industry; Drugs, Generic; Europe; Humans; Leukemia, Myeloid, Acute; National Cancer Institute (U.S.); Patient Selection; Survival Analysis; Time Factors; United States; United States Food and Drug Administration	2012
Fatal palmar-plantar erythrodysesthesia after clofarabine and cytarabine chemotherapy. Acta haematologica, 2012, Volume: 128, Issue:3 Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Clofarabine; Cytarabine; Fatal Outcome; Hand-Foot Syndrome; Humans; Leukemia, Myeloid, Acute	2012
A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia. Oncotarget, 2012, Volume: 3, Issue:12 Topics: Adenine Nucleotides; ADP-ribosyl Cyclase 1; Allosteric Regulation; Antigens, CD34; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arabinonucleosides; Autophagy; Cell Line, Tumor; Clofarabine; Dose-Response Relationship, Drug; Drug Synergism; Eukaryotic Initiation Factor-4F; Extracellular Signal-Regulated MAP Kinases; G1 Phase Cell Cycle Checkpoints; Humans; Interleukin-3 Receptor alpha Subunit; Leukemia, Myeloid, Acute; Membrane Glycoproteins; Phosphatidylinositol 3-Kinase; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Signal Transduction; Sirolimus; STAT3 Transcription Factor; Time Factors; TOR Serine-Threonine Kinases; Tumor Cells, Cultured	2012
Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation. Clinical lymphoma, myeloma & leukemia, 2013, Volume: 13, Issue:2 Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Liver Diseases; Male; Middle Aged; Remission Induction; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome	2013
Induction of complete remission using single agent clofarabine in a patient with primary refractory acute myeloblaste leukemia. Leukemia & lymphoma, 2003, Volume: 44, Issue:12 Topics: Adenine Nucleotides; Adult; Antineoplastic Agents; Arabinonucleosides; Clinical Trials as Topic; Clofarabine; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Acute; Male; Nucleosides; Prognosis; Purines; Remission Induction	2003
Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia. Journal of clinical pharmacology, 2004, Volume: 44, Issue:11 Topics: Adenine Nucleotides; Adolescent; Adult; Arabinonucleosides; Child; Child, Preschool; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clofarabine; Computer Simulation; Half-Life; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Metabolic Clearance Rate; Models, Biological; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Reproducibility of Results	2004
Saccharomyces cerevisiae emboli in an immunocompromised patient with relapsed acute myeloid leukaemia. Clinical and experimental dermatology, 2007, Volume: 32, Issue:4 Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Clofarabine; Dermatomycoses; Female; Humans; Immunocompromised Host; Leukemia, Myeloid, Acute; Middle Aged; Opportunistic Infections; Recurrence; Saccharomyces cerevisiae	2007
Biochemical pharmacology and resistance to 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, a novel analogue of cladribine in human leukemic cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:9 Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Cladribine; Clofarabine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; HL-60 Cells; Humans; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Leukemia, T-Cell; Phosphorylation; Recombinant Proteins; Tumor Cells, Cultured	1999